AKTS (Aktis Oncology, Inc. Common stock)
Insider Trading Activity
Every open-market purchase and sale reported by AKTS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-21 | Ken Herrmann | Director | MIXED | — | — |
| 2026-07-20 | Ken Herrmann | Director | MIXED | — | — |
| 2026-07-10 | Shulamit Ron-Bigger | Chief Operating Officer | MIXED | — | — |
| 2026-07-10 | Akos Czibere | Chief Medical Officer | MIXED | — | — |
| 2026-04-16 | Glenn Gormley | Director | A | — | — |
| 2026-01-14 | MPM ASSET MANAGEMENT LLC | 10%+ Owner | MIXED | — | — |
| 2026-01-14 | MPM ONCOLOGY INNOVATIONS FUND LP | 10%+ Owner | MIXED | — | — |
| 2026-01-14 | Todd Foley | Director | MIXED | — | — |
| 2026-01-12 | Lloyd Mitchell Segal | Director | C | — | — |
| 2026-01-12 | Helen Susan Kim | Director | MIXED | — | — |
| 2026-01-12 | OLEG NODELMAN | Director | MIXED | — | — |
| 2026-01-12 | VIDA VENTURES II-A, LLC | 10%+ Owner | MIXED | — | — |
| 2024-01-31 | Kenneth Boller | CFO | Buy | — | — |
| 2024-01-31 | Jeffrey B. Shealy | Chief Executive Officer | Buy | — | — |
| 2024-01-31 | Arthur Geiss | Director | Buy | — | — |
| 2024-01-31 | David Aichele | EVP of Business Development | Buy | — | — |
| 2023-12-20 | Kenneth Boller | CFO | Sell | — | — |
| 2023-12-20 | David Aichele | EVP of Business Development | Sell | — | — |
| 2023-11-22 | David Aichele | EVP of Business Development | Sell | — | — |
| 2023-11-22 | Kenneth Boller | CFO | Sell | — | — |
| 2023-11-08 | Steven Denbaars | Director | A | — | — |
| 2023-11-08 | JERRY D NEAL | Director | A | — | — |
| 2023-11-08 | Jeffrey McMahon | Director | A | — | — |
| 2023-11-08 | Arthur Geiss | Director | A | — | — |
| 2023-11-08 | James Michael McGuire | Director | A | — | — |
| 2023-11-08 | Michelle Petock | Director | A | — | — |
| 2023-11-08 | SUZANNE B RUDY | Director | A | — | — |
| 2023-09-28 | Jeffrey B. Shealy | Chief Executive Officer | A | — | — |
| 2023-09-15 | David Aichele | EVP of Business Development | A | — | — |
| 2023-09-15 | Kenneth Boller | CFO | A | — | — |
| 2023-09-13 | David Aichele | EVP of Business Development | Sell | — | — |
| 2023-09-13 | Kenneth Boller | CFO | Sell | — | — |
| 2023-08-22 | Steven Denbaars | Director | Sell | — | — |
| 2023-03-23 | Michelle Petock | Director | A | — | — |
| 2023-03-10 | James Michael McGuire | Director | A | — | — |
| 2023-02-14 | Kenneth Boller | CFO | Sell | — | — |
| 2023-01-25 | Steven Denbaars | Director | A | — | — |
| 2023-01-24 | Jeffrey B. Shealy | Chief Executive Officer | A | — | — |
| 2022-12-21 | David Aichele | EVP of Business Development | Sell | — | — |
| 2022-12-21 | Jeffrey B. Shealy | Chief Executive Officer | Sell | — | — |
| 2022-12-21 | Kenneth Boller | CFO | Sell | — | — |
| 2022-12-08 | Steven Denbaars | Director | Sell | — | — |
| 2022-11-28 | David Aichele | EVP of Business Development | Sell | — | — |
| 2022-11-28 | Jeffrey B. Shealy | Chief Executive Officer | Sell | — | — |
| 2022-11-28 | Kenneth Boller | CFO | Sell | — | — |
| 2022-11-23 | David Aichele | EVP of Business Development | A | — | — |
| 2022-11-23 | Kenneth Boller | CFO | A | — | — |
| 2022-11-23 | Jeffrey B. Shealy | Chief Executive Officer | A | — | — |
| 2022-11-14 | JERRY D NEAL | Director | A | — | — |
| 2022-11-14 | Arthur Geiss | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 7,570,168 | — |
| — | Director | 4,859,370 | — |
| — | Director | 4,002,533 | — |
| — | 10%+ Owner | 1,655,971 | — |
| — | Director | 347,305 | — |
| — | 10%+ Owner | 134,842 | — |
| — | Chief Operating Officer | 34,200 | — |
| — | Director | 19,631 | — |
| — | Director | 4,856 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AKTS quote page; the site-wide leaderboard is on the insider transactions hub.